Treatments for COVID-19
The treatment for COVID-19 has evolved rapidly since the start of the pandemic and now consists mainly of antiviral and immunomodulatory agents. Antivirals, such as remdesivir and nirmatrelvir-ritonavir, have proved to be most useful earlier in illness (e.g., as outpatient therapy) and for less severe disease. Immunomodulatory therapies, such as dexamethasone and interleukin-6 or Janus kinase inhibitors, are most useful in severe disease or critical illness. The role of anti-SARS-CoV-2 monoclonal antibodies has diminished because of the emergence of viral variants that are not anticipated to be susceptible to these treatments, and there still is not a consensus on the use of convalescent plasma. COVID-19 has been associated with increased rates of venous thromboembolism, but the role of antithrombotic therapy is limited. Multiple investigational agents continue to be studied, which will alter current treatment paradigms as new data are released.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:75 |
|---|---|
| Enthalten in: |
Annual review of medicine - 75(2024) vom: 29. Jan., Seite 145-157 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Andrews, Hayden S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antithrombotic therapy |
|---|
| Anmerkungen: |
Date Completed 30.01.2024 Date Revised 30.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1146/annurev-med-052422-020316 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362195447 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362195447 | ||
| 003 | DE-627 | ||
| 005 | 20240130232033.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1146/annurev-med-052422-020316 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1275.xml |
| 035 | |a (DE-627)NLM362195447 | ||
| 035 | |a (NLM)37722709 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Andrews, Hayden S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatments for COVID-19 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.01.2024 | ||
| 500 | |a Date Revised 30.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The treatment for COVID-19 has evolved rapidly since the start of the pandemic and now consists mainly of antiviral and immunomodulatory agents. Antivirals, such as remdesivir and nirmatrelvir-ritonavir, have proved to be most useful earlier in illness (e.g., as outpatient therapy) and for less severe disease. Immunomodulatory therapies, such as dexamethasone and interleukin-6 or Janus kinase inhibitors, are most useful in severe disease or critical illness. The role of anti-SARS-CoV-2 monoclonal antibodies has diminished because of the emergence of viral variants that are not anticipated to be susceptible to these treatments, and there still is not a consensus on the use of convalescent plasma. COVID-19 has been associated with increased rates of venous thromboembolism, but the role of antithrombotic therapy is limited. Multiple investigational agents continue to be studied, which will alter current treatment paradigms as new data are released | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a COVID-19 treatment | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antithrombotic therapy | |
| 650 | 4 | |a antivirals | |
| 650 | 4 | |a convalescent plasma | |
| 650 | 4 | |a immunomodulators | |
| 650 | 4 | |a neutralizing antibodies | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Janus Kinase Inhibitors |2 NLM | |
| 700 | 1 | |a Herman, Jonathan D |e verfasserin |4 aut | |
| 700 | 1 | |a Gandhi, Rajesh T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annual review of medicine |d 1950 |g 75(2024) vom: 29. Jan., Seite 145-157 |w (DE-627)NLM00007831X |x 1545-326X |7 nnns |
| 773 | 1 | 8 | |g volume:75 |g year:2024 |g day:29 |g month:01 |g pages:145-157 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1146/annurev-med-052422-020316 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 75 |j 2024 |b 29 |c 01 |h 145-157 | ||